+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Respiratory Tract Infections Drug Development Pipeline Review, 2018

  • ID: 4606289
  • Report
  • Region: Global
  • 153 pages
  • GBI Research
1 of 3

FEATURED COMPANIES

  • Abera Bioscience AB
  • Bioversys AG
  • Diphtheria
  • Globeimmune Inc
  • LegoChem Biosciences Inc
  • Qurient Co Ltd
  • MORE
Respiratory Tract Infections Drug Development Pipeline Review, 2018

Summary

Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in the body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest. There are 206 products in development for this indication.

Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics. There are 31 products in development for this indication.

Pertussis is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antibiotics. There are 40 products in development for this indication.

Molecular targets acted on by products in development for respiratory tract infections include bacterial proteins and toxins. Companies operating in this pipeline space include Beijing Minhai Biotechnology, Sanofi and GlaxoSmithKline.

This report “Respiratory Tract Infections Drug Development Pipeline Review, 2018”provides an overview of the pipeline landscape for respiratory tract infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for tuberculosis, diphtheria and pertussis (whooping cough), and features dormant and discontinued products.

Scope
  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abera Bioscience AB
  • Bioversys AG
  • Diphtheria
  • Globeimmune Inc
  • LegoChem Biosciences Inc
  • Qurient Co Ltd
  • MORE

1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Respiratory Tract Infections Report Coverage
2.2 Tuberculosis - Overview
2.3 Diphtheria - Overview
2.4 Pertussis (Whooping Cough) - Overview

3 Therapeutics Development
3.1 Tuberculosis
3.2 Diphtheria
3.3 Pertussis (Whooping Cough)

4 Therapeutics Assessment
4.1 Tuberculosis
4.2 Diphtheria
4.3 Pertussis (Whooping Cough)

5 Companies Involved in Therapeutics Development
5.1 Tuberculosis
5.2 Diphtheria
5.3 Pertussis (Whooping Cough)

6 Dormant Projects
6.1 Tuberculosis
6.2 Diphtheria
6.3 Pertussis (Whooping Cough)

7 Discontinued Products
7.1 Tuberculosis
7.2 Diphtheria
7.3 Pertussis (Whooping Cough)

8 Product Development Milestones
8.1 Tuberculosis
8.2 Diphtheria
8.3 Pertussis (Whooping Cough)

9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation
9.6 Contact Us
9.7 Disclaimer

1.1 List of Tables
Table 1: Number of Products under Development for Tuberculosis
Table 2: Number of Products under Development by Companies Tuberculosis
Table 3: Number of Products under Development by Universities/Institutes Tuberculosis
Table 4: Products under Development by Companies Tuberculosis
Table 5: Products under Development by Universities/Institutes Tuberculosis
Table 6: Number of Products under Development for Diphtheria
Table 7: Number of Products under Development by Companies Diphtheria
Table 8: Number of Products under Development by Universities/Institutes Diphtheria
Table 9: Products under Development by Companies Diphtheria
Table 10: Products under Development by Universities/Institutes Diphtheria
Table 11: Number of Products under Development for Pertussis (Whooping Cough)
Table 12: Number of Products under Development by Companies Pertussis (Whooping Cough)
Table 13: Number of Products under Development by Universities/Institutes Pertussis (Whooping Cough)
Table 14: Products under Development by Companies Pertussis (Whooping Cough)
Table 15: Products under Development by Universities/Institutes Pertussis (Whooping Cough)
Table 16: Number of Products by Stage and Target Tuberculosis
Table 17: Number of Products by Stage and Mechanism of Action Tuberculosis
Table 18: Number of Products by Stage and Route of Administration Tuberculosis
Table 19: Number of Products by Stage and Molecule Type Tuberculosis
Table 20: Number of Products by Stage and Target Diphtheria
Table 21: Number of Products by Stage and Route of Administration Diphtheria
Table 22: Number of Products by Stage and Molecule Type Diphtheria
Table 23: Number of Products by Stage and Target Pertussis (Whooping Cough)
Table 24: Number of Products by Stage and Mechanism of Action Pertussis (Whooping Cough)
Table 25: Number of Products by Stage and Route of Administration Pertussis (Whooping Cough)
Table 26: Number of Products by Stage and Molecule Type Pertussis (Whooping Cough)
Table 27: Tuberculosis - Pipeline by Abera Bioscience AB
Table 28: Tuberculosis - Pipeline by AGILeBiotics BV
Table 29: Tuberculosis - Pipeline by Akshaya Bio Inc
Table 30: Tuberculosis - Pipeline by Archivel Farma SL
Table 31: Tuberculosis - Pipeline by AstraZeneca Plc
Table 32: Tuberculosis - Pipeline by Aucta Pharmaceuticals LLC
Table 33: Tuberculosis - Pipeline by BioLingus AG
Table 34: Tuberculosis - Pipeline by Bioversys AG
Table 35: Tuberculosis - Pipeline by Celgene Corp
Table 36: Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co Ltd
Table 37: Tuberculosis - Pipeline by Consegna Pharma Inc
Table 38: Tuberculosis - Pipeline by Crestone Inc
Table 39: Tuberculosis - Pipeline by Daiichi Sankyo Co Ltd
Table 40: Tuberculosis - Pipeline by Demuris Ltd
Table 41: Tuberculosis - Pipeline by Eisai Co Ltd
Table 42: Tuberculosis - Pipeline by Eli Lilly and Co
Table 43: Tuberculosis - Pipeline by EpiVax Inc
Table 44: Tuberculosis - Pipeline by Evotec AG
Table 45: Tuberculosis - Pipeline by FIT Biotech Oy
Table 46: Tuberculosis - Pipeline by GangaGen Inc
Table 47: Tuberculosis - Pipeline by GC Pharma
Table 48: Tuberculosis - Pipeline by GlaxoSmithKline Plc
Table 49: Tuberculosis - Pipeline by Globeimmune Inc
Table 50: Tuberculosis - Pipeline by Hager Biosciences LLC
Table 51: Tuberculosis - Pipeline by Hsiri Therapeutics LLC
Table 52: Tuberculosis - Pipeline by Immodulon Therapeutics Ltd
Table 53: Tuberculosis - Pipeline by Immunitor Inc

1.2 List of Figures
Figure 1: Number of Products under Development for Tuberculosis
Figure 2: Number of Products under Development by Companies Tuberculosis
Figure 3: Number of Products under Development by Universities/Institutes Tuberculosis
Figure 4: Number of Products under Development for Diphtheria
Figure 5: Number of Products under Development by Companies Diphtheria
Figure 6: Number of Products under Development by Universities/Institutes Diphtheria
Figure 7: Number of Products under Development for Pertussis (Whooping Cough)
Figure 8: Number of Products under Development by Companies Pertussis (Whooping Cough)
Figure 9: Number of Products under Development by Universities/Institutes Pertussis (Whooping Cough)
Figure 10: Number of Products by Top 10 Targets Tuberculosis
Figure 11: Number of Products by Stage and Top 10 Targets Tuberculosis
Figure 12: Number of Products by Top 10 Mechanism of Actions Tuberculosis
Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions Tuberculosis
Figure 14: Number of Products by Routes of Administration Tuberculosis
Figure 15: Number of Products by Stage and Routes of Administration Tuberculosis
Figure 16: Number of Products by Top 10 Molecule Types Tuberculosis
Figure 17: Number of Products by Stage and Top 10 Molecule Types Tuberculosis
Figure 18: Number of Products by Targets Diphtheria
Figure 19: Number of Products by Stage and Targets Diphtheria
Figure 20: Number of Products by Routes of Administration Diphtheria
Figure 21: Number of Products by Stage and Routes of Administration Diphtheria
Figure 22: Number of Products by Molecule Types Diphtheria
Figure 23: Number of Products by Stage and Molecule Types Diphtheria
Figure 24: Number of Products by Targets Pertussis (Whooping Cough)
Figure 25: Number of Products by Stage and Targets Pertussis (Whooping Cough)
Figure 26: Number of Products by Routes of Administration Pertussis (Whooping Cough)
Figure 27: Number of Products by Stage and Routes of Administration Pertussis (Whooping Cough)
Figure 28: Number of Products by Top 10 Molecule Types Pertussis (Whooping Cough)
Figure 29: Number of Products by Stage and Molecule Types Pertussis (Whooping Cough)

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abera Bioscience AB
  • AGILeBiotics BV
  • Akshaya Bio Inc
  • Archivel Farma SL
  • AstraZeneca Plc
  • Aucta Pharmaceuticals LLC
  • Beijing Minhai Biotechnology Co Ltd
  • Bharat Biotech Ltd
  • BioLingus AG
  • Biological E Ltd
  • Bioversys AG
  • BlueWillow Biologics
  • Boryung Pharmaceutical Co Ltd
  • Cadila Healthcare Ltd
  • Celgene Corp
  • Chongqing Zhifei Biological Products Co Ltd
  • Consegna Pharma Inc
  • Crestone Inc
  • Daiichi Sankyo Co Ltd
  • DBV Technologies SA
  • Demuris Ltd
  • Diphtheria
  • Eisai Co Ltd
  • Eli Lilly and Co
  • EpiVax Inc
  • Evotec AG
  • FIT Biotech Oy
  • GangaGen Inc
  • GC Pharma
  • GlaxoSmithKline Plc
  • Globeimmune Inc
  • Hager Biosciences LLC
  • Hsiri Therapeutics LLC
  • Immodulon Therapeutics Ltd
  • Immunitor Inc
  • ImmunoBiology Ltd
  • Indian Immunologicals Ltd
  • Innovare R & D SA De CV
  • Inovio Pharmaceuticals Inc
  • Johnson & Johnson
  • Kaketsuken
  • LegoChem Biosciences Inc
  • LG Chem Ltd
  • Matinas BioPharma Holdings Inc
  • Merck & Co Inc
  • Microbiotix Inc
  • Novartis AG
  • NovoBiotic Pharmaceuticals LLC
  • Otsuka Holdings Co Ltd
  • Panacea Biotec Ltd
  • Pertussis (Whooping Cough)
  • Pfizer Inc
  • QureTech Bio AB
  • Qurient Co Ltd
  • Recce Ltd
  • Rodos BioTarget GmbH
  • Sanofi
  • Sanofi Pasteur SA
  • Sequella Inc
  • Serum Institute of India Ltd
  • Shantha Biotechnics Pvt Ltd
  • Shionogi & Co Ltd
  • Synthetic Biologics Inc
  • Takeda Pharmaceutical Co Ltd
  • Target Medicals LLC
  • Theravectys SA
  • TVAX Biomedical Inc
  • Vaccibody AS
  • Vakzine Projekt Management GmbH
  • Vaxil Bio Therapeutics Ltd
  • Vaxine Pty Ltd
  • Vichem Chemie Research Ltd
  • Wockhardt Ltd
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4606289
Adroll
adroll